Publications by authors named "Russell David Anderson"

Background: Stromal cell-derived factor-1 (SDF-1) promotes tissue repair through mechanisms of cell survival, endogenous stem cell recruitment, and vasculogenesis. Stromal Cell-Derived Factor-1 Plasmid Treatment for Patients with Heart Failure (STOP-HF) is a Phase II, double-blind, randomized, placebo-controlled trial to evaluate safety and efficacy of a single treatment of plasmid stromal cell-derived factor-1 (pSDF-1) delivered via endomyocardial injection to patients with ischaemic heart failure (IHF).

Methods: Ninety-three subjects with IHF on stable guideline-based medical therapy and left ventricular ejection fraction (LVEF) ≤40%, completed Minnesota Living with Heart Failure Questionnaire (MLWHFQ) and 6-min walk distance (6 MWD), were randomized 1 : 1 : 1 to receive a single treatment of either a 15 or 30 mg dose of pSDF-1 or placebo via endomyocardial injections.

View Article and Find Full Text PDF

Synopsis of recent research by authors named "Russell David Anderson"

  • - Russell David Anderson's research primarily focuses on the application of non-viral gene therapy in treating chronic ischaemic heart failure, specifically exploring the effects of stromal cell-derived factor-1 (SDF-1) on ventricular remodeling and clinical outcomes.
  • - His noteworthy study, the STOP-HF randomized Phase II trial, demonstrated the safety and efficacy of plasmid SDF-1 (pSDF-1) administration via endomyocardial injection, which showed promising results in improving the quality of life and physical function of patients with ischaemic heart failure.
  • - The trial involved a robust design with 93 subjects and utilized validated measures such as the Minnesota Living with Heart Failure Questionnaire and 6-minute walk distance to assess the impact of gene therapy on patients' health status post-treatment.